Growth Metrics

Biogen (BIIB) Long-Term Deferred Tax (2017 - 2026)

Biogen has reported Long-Term Deferred Tax over the past 10 years, most recently at $238.2 million for Q1 2026.

  • For Q1 2026, Long-Term Deferred Tax fell 22.54% year-over-year to $238.2 million; the TTM value through Mar 2026 reached $238.2 million, down 22.54%, while the annual FY2025 figure was $292.5 million, 9.78% down from the prior year.
  • Long-Term Deferred Tax for Q1 2026 was $238.2 million at Biogen, down from $292.5 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $1.3 billion in Q1 2022 and troughed at $238.2 million in Q1 2026.
  • A 5-year average of $819.5 million and a median of $928.6 million in 2023 define the central range for Long-Term Deferred Tax.
  • Biggest five-year swings in Long-Term Deferred Tax: rose 0.19% in 2022 and later tumbled 67.75% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $1.2 billion in 2022, then fell by 24.28% to $928.6 million in 2023, then plummeted by 65.09% to $324.2 million in 2024, then dropped by 9.78% to $292.5 million in 2025, then decreased by 18.56% to $238.2 million in 2026.
  • Business Quant data shows Long-Term Deferred Tax for BIIB at $238.2 million in Q1 2026, $292.5 million in Q4 2025, and $312.4 million in Q3 2025.